Explore by Category

XPOVIO (selinexor) Study Shows Impact When Used in Earlier Lines of Multiple Myeloma Therapy with Velcade and Dex

CLINICAL TRIALS - March 11, 2020

Using XPOVIO (selinexor) and Velcade weekly with low-dose dexamethasone showed a 47% increase in progression free survival compared to Velcade (twice weekly) ... Read More

Clinical Trial: Smoldering Myeloma Personalized Vaccine at MD Anderson

CLINICAL TRIALS - February 06, 2020

Could a vaccine prevent smoldering myeloma from progressing to active myeloma? An early Phase I clinical trial at MD Anderson Cancer Center is developing a pers... Read More

Clinical Trial: Daratumumab, Cytoxan, Dex and Velcade for Newly Diagnosed and Relapsed Myeloma

CLINICAL TRIALS - January 07, 2017

Daratumumab is now being used in many clinical trials in many different combinations. Because of its success in past clinical trials, it is moving to earlier us... Read More

An Update on INSIGHT Global Study (for Myeloma Treatment Effectiveness and Outcomes)

CLINICAL TRIALS - December 21, 2016

BY JIM OMEL In July, 2016 I explained INSIGHT, a truly global study of treatment and outcome data for myeloma patients gathered from around the world. The go... Read More

Clinical Trial: Adding Daratumumab to the Frontline for Newly Diagnosed Myeloma Patients

CLINICAL TRIALS - December 17, 2016

A new study is open at the Levine Cancer Institute (with many more sites to follow) adding daratumumab to Revlimid, Velcade and dexamethasone for newly diagnose... Read More

Clinical Trial: New Oral Myeloma Drug for Relapsed/Refractory Myeloma

CLINICAL TRIALS - November 11, 2016

A new oral drug called ONC201 is being tested in a Phase 2 study. The drug is given orally once every 3 weeks as a single drug to patients with relapsed/refract... Read More


Thanks to our site sponsors: